Literature DB >> 26747210

The relationship between aquaglyceroporin expression and development of fatty liver in diet-induced obesity and ob/ob mice.

Satoshi Hirako1, Yoshihiro Wakayama2, Hyounju Kim3, Yuzuru Iizuka3, Akiyo Matsumoto3, Nobuhiro Wada4, Ai Kimura5, Mai Okabe6, Junichi Sakagami7, Mamiko Suzuki8, Fumiko Takenoya9, Seiji Shioda10.   

Abstract

Aquaporin (AQP) 7 and AQP9 are subcategorised as aquaglyceroporins which transport glycerin in addition to water. These AQPs may play a role in the homeostasis of energy metabolism. We examined the effect of AQP7, AQP9, and lipid metabolism-related gene expression in obese mice. In diet-induced obese (DIO) mice, excess lipid accumulated in the liver, which was hyperleptinemic and hyperinsulinemic. Hepatic AQP9 gene expression was significantly increased in both DIO and ob/ob mice compared to controls. The mRNA expression levels of fatty acid and triglyceride synthesis-related genes and fatty acid β oxidation-related genes in the liver were also higher in both mouse models, suggesting that triglyceride synthesis in this organ is promoted as a result of glycerol release from adipocytes. Adipose AQP7 and AQP9 gene expressions were increased in DIO mice, but there was no difference in ob/ob mice compared to wild-type mice. In summary, adipose AQP7 and AQP9 gene expressions are increased by diet-induced obesity, indicating that this is one of the mechanisms by which lipid accumulates in response to a high fat diet, not the genetic mutation of ob/ob mice. Hepatic AQP9 gene expression was increased in both obesity model mice. AQP7 and AQP9 therefore have the potential of defining molecules for the characterisation of obesity or fatty liver and may be a target molecules for the treatment of those disease.
Copyright © 2015 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AQP7; AQP9; Hepatic lipids; Lipid metabolism; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26747210     DOI: 10.1016/j.orcp.2015.12.001

Source DB:  PubMed          Journal:  Obes Res Clin Pract        ISSN: 1871-403X            Impact factor:   2.288


  7 in total

Review 1.  Hepatocyte and Sertoli Cell Aquaporins, Recent Advances and Research Trends.

Authors:  Raquel L Bernardino; Raul A Marinelli; Anna Maggio; Patrizia Gena; Ilaria Cataldo; Marco G Alves; Maria Svelto; Pedro F Oliveira; Giuseppe Calamita
Journal:  Int J Mol Sci       Date:  2016-07-09       Impact factor: 5.923

2.  Glycerol contained in vaping liquids affects the liver and aspects of energy homeostasis in a sex-dependent manner.

Authors:  Ariane Lechasseur; Mathilde Mouchiroud; Félix Tremblay; Gabrielle Bouffard; Nadia Milad; Marie Pineault; Michaël Maranda-Robitaille; Joanie Routhier; Marie-Josée Beaulieu; Sophie Aubin; Mathieu Laplante; Mathieu C Morissette
Journal:  Physiol Rep       Date:  2022-01

Review 3.  Aquaglyceroporins: Drug Targets for Metabolic Diseases?

Authors:  Giuseppe Calamita; Jason Perret; Christine Delporte
Journal:  Front Physiol       Date:  2018-07-10       Impact factor: 4.566

4.  High-fat diet effects on amniotic fluid volume and amnion aquaporin expression in non-human primates.

Authors:  Cecilia Y Cheung; Victoria H J Roberts; Antonio E Frias; Robert A Brace
Journal:  Physiol Rep       Date:  2018-07

Review 5.  Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy.

Authors:  Giovanni Tarantino; Vincenzo Citro; Domenico Capone
Journal:  J Clin Med       Date:  2019-12-19       Impact factor: 4.241

6.  In silico simulations of erythrocyte aquaporins with quantitative in vitro validation.

Authors:  Ruth Chan; Michael Falato; Huiyun Liang; Liao Y Chen
Journal:  RSC Adv       Date:  2020-06-04       Impact factor: 4.036

7.  Sex-Specific Effect of High-Fat Diet on Glycerol Metabolism in Murine Adipose Tissue and Liver.

Authors:  Francesco Maria Iena; Johanne Blanner Jul; Jens Bay Vegger; Andreas Lodberg; Jesper Skovhus Thomsen; Annemarie Brüel; Janne Lebeck
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.